Stay updated with breaking news from Mis 416. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
News, analysis and interviews with politicians and observers. When the public trial for the drug was about to be announced as a failure. Want to read a little from the complaint. Mis 416 had the potential to be an enormously profitable if the drug trial was successful. The drug, however, failed the drug trial. Public announcement of these results caused the stock price to drop by 92 . In or about june of 2017, Christopher Collins violated the duties he owed to innate by Passing Material Nonpublic information regarding the Drug Trial Results to his son the defendant so that Cameron Collins could use that information to make timely trades in innate stock and tip others. In detail, it was stunning from the actual complaint itself, those phone call ....
Interviews with political figures and news updates. Interviews with political figures and news updates. Able to sell the shares. They have telephone logs, who called whom and when. It appears they have people helping the government out with the testimony. As mimi said, andrea, its kind of overwhelming evidence thats difficult for federal prosecutors to ignore. And chuck todd, weve not yet seen to my knowledge a tweet from the president or any suggestion that this is witch hunt, mueller related. But this is really separate, this is an investigation that started, there was an Ethics Investigation that we heard about some months back, last year sometime. And so this does not come from the Mueller Operation at all. Right. And thats the thing, it has zero to do this is just bad timing, bad coincidence. And it looks bad, right . Here is yet another person close to the pres ....
When the public trial for the drug was about to be announced as a failure. want to read a little from the complaint. mis 416 had the potential to be an enormously profitable if the drug trial was successful. the drug, however, failed the drug trial. public announcement of these results caused the stock price to drop by 92%. in or about june of 2017, christopher collins violated the duties he owed to innate by passing material nonpublic information regarding the drug trial results to his son the defendant so that cameron collins could use that information to make timely trades in innate stock and tip others. in detail, it was stunning from the actual complaint itself, those phone calls or the initial ones from the congressman to his sn, they took place on the grounds of the white house, during the white house congressional picnic. anybody who has been paying attention to chris collins on capitol hill the last couple of years it was no secret his role in this company, his belief in this ....
Prior to the market close of june 26. after the market closes, innate announces to the public that its drug had failed the trial. and the next day, the drug price, the price of innate, falls off a cliff. it drops 92% in value in a single day. this was the drop that was anticipated by the co-conspirators. this was the drop in value that the co-conspirators avoided by selling their shares for the public announcement. and they could only sell those shares by virtue of the initial tip of inside information by congressman collins. a case of this type and significance, obviously, involves the s.e.c. and the fbi ....
thank you, geoff. good afternoon, everybody. u.s. representative christopher collins sat on innate s board of directors for a period of more than three years. spanning the run-up to the drug trial announcement in mid-2017. collins himself was the company s largest shareholder. in or about the summer of 2017, a drug designed to treat a debilitating form of multiple sclerosis had entered the late stages of a phase 2b clinical trial. this drug, mis-416, was the only viable drug in the pipeline for innate. this is significant in that the company s value was nearly completely wrapped up in the success of the clinical trial and subsequent phase three trial. on the evening of june 22nd, 2017, collins received an e-mail informing him that mis-416 had failed its clinical trial. ....